CSO Harriet L. Robinson Honored as Distinguished Emeritus Faculty
Chairman David A. Dodd To Receive Alumni Award from Georgia State University
ATLANTA - September 29, 2011 - GeoVax Labs, Inc. (OTCBB:GOVX), an Atlanta-based
biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus
(HIV) infections, announces that both its Chief Scientific Officer and its Chairman are to receive
academic honors on September 26 and October 21, respectively.
On September 26, Chief Scientific Officer Harriet L. Robinson, PhD, was honored as a Distinguished
Faculty Member by the Emory University Emeritus College. This is an association of Emory's retired
faculty and administrative staff who have joined together to advance their intellectual interests, to serve
the University, and their University colleagues. The honor is bestowed to individuals for outstanding
accomplishments and service to the University and its community. Dr. Robinson was honored for her
ongoing work on the development of an effective HIV/AIDS vaccine. She has tirelessly devoted her
career to finding a way to prevent and potentially cure this disease.
On October 21, Chairman David A. Dodd will receive the Distinguished Alumni Achievement Award
from Georgia State University. This award is bestowed annually to a graduate of the University in
recognition of outstanding professional and personal achievements in any field of endeavor. Mr. Dodd is
one of only two alumni to receive the award this year. During his career, Mr. Dodd was the CEO of a
number of successful pharmaceutical companies including Solvay and Serologicals Corporation. More
recently, he has been engaged in starting new businesses focused on vaccines. Throughout his career, he
has been an active contributor of time and talent helping civic, industry, and economic growth
Robert T. McNally, PhD, President and CEO of GeoVax Labs, said, "We are proud to see Harriet and
David being honored by the academic institutions with which they have been affiliated in the past. This
recognition is well deserved."
About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include developing AIDS
vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions
(FDA guidelines), conducting human trials for vaccine safety and effectiveness, and obtaining
regulatory approvals to move the product forward. All preventative phase 1 human clinical trials
conducted to date tested various combinations and doses of our DNA and MVA AIDS vaccines in
human volunteers for their demonstrated ability to raise anti-HIV immune responses as well as for their
safety. Successful results from all phase 1 testing supported the initiation of the first phase 2 testing.
GeoVax's phase 2 human trial began in January 2009 and will involve 225 participants at sites in the
United States and South America. Long term, we expect that GeoVax will grant manufacturing and
distribution rights in several global markets in return for upfront fees, collaborative development
agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and
distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.
Certain statements in this document are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in
these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these
vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use,
GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is
development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax
will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which
GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and
Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
The Investor Relations Group
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
"Reproduced with permission - GeoVax Labs, Inc."
GeoVax Labs, Inc.